173 related articles for article (PubMed ID: 36057616)
21. Alzheimer's Disease Diagnosis Based on the Amyloid, Tau, and Neurodegeneration Scheme (ATN) in a Real-Life Multicenter Cohort of General Neurological Centers.
Baldeiras I; Silva-Spínola A; Lima M; Leitão MJ; Durães J; Vieira D; Tábuas-Pereira M; Cruz VT; Rocha R; Alves L; Machado Á; Milheiro M; Santiago B; Santana I
J Alzheimers Dis; 2022; 90(1):419-432. PubMed ID: 36120784
[TBL] [Abstract][Full Text] [Related]
22. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
23. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
24. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
25. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
26. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.
Ossenkoppele R; Pichet Binette A; Groot C; Smith R; Strandberg O; Palmqvist S; Stomrud E; Tideman P; Ohlsson T; Jögi J; Johnson K; Sperling R; Dore V; Masters CL; Rowe C; Visser D; van Berckel BNM; van der Flier WM; Baker S; Jagust WJ; Wiste HJ; Petersen RC; Jack CR; Hansson O
Nat Med; 2022 Nov; 28(11):2381-2387. PubMed ID: 36357681
[TBL] [Abstract][Full Text] [Related]
27. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
28. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
29. Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology.
Guo T; Korman D; Baker SL; Landau SM; Jagust WJ;
Biol Psychiatry; 2021 Apr; 89(8):786-794. PubMed ID: 32919611
[TBL] [Abstract][Full Text] [Related]
30. Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders.
Régy M; Dugravot A; Sabia S; Bouaziz-Amar E; Paquet C; Hanseeuw B; Singh-Manoux A; Dumurgier J
Alzheimers Res Ther; 2023 Apr; 15(1):77. PubMed ID: 37038213
[TBL] [Abstract][Full Text] [Related]
31. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.
Timmers T; Ossenkoppele R; Verfaillie SCJ; van der Weijden CWJ; Slot RER; Wesselman LMP; Windhorst AD; Wolters EE; Yaqub M; Prins ND; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BNM
Neurobiol Aging; 2019 Jul; 79():50-58. PubMed ID: 31026622
[TBL] [Abstract][Full Text] [Related]
32. MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum.
Lew CO; Zhou L; Mazurowski MA; Doraiswamy PM; Petrella JR;
Radiology; 2023 Oct; 309(1):e222441. PubMed ID: 37815445
[TBL] [Abstract][Full Text] [Related]
33. Association of weight change with cerebrospinal fluid biomarkers and amyloid positron emission tomography in preclinical Alzheimer's disease.
Grau-Rivera O; Navalpotro-Gomez I; Sánchez-Benavides G; Suárez-Calvet M; Milà-Alomà M; Arenaza-Urquijo EM; Salvadó G; Sala-Vila A; Shekari M; González-de-Echávarri JM; Minguillón C; Niñerola-Baizán A; Perissinotti A; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Molinuevo JL;
Alzheimers Res Ther; 2021 Feb; 13(1):46. PubMed ID: 33597012
[TBL] [Abstract][Full Text] [Related]
34. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
35. Validation of the Alzheimer Disease Dementia Conversion-Related Pattern as an ATN Biomarker of Neurodegeneration.
Blazhenets G; Frings L; Ma Y; Sörensen A; Eidelberg D; Wiltfang J; Meyer PT;
Neurology; 2021 Mar; 96(9):e1358-e1368. PubMed ID: 33408150
[TBL] [Abstract][Full Text] [Related]
36. Amyloid-Tau-Neurodegeneration Profiles and Longitudinal Cognition in Sporadic Young-Onset Dementia.
Vipin A; Koh CL; Wong BYX; Zailan FZ; Tan JY; Soo SA; Satish V; Kumar D; Wang BZ; Ng ASL; Chiew HJ; Ng KP; Kandiah N
J Alzheimers Dis; 2022; 90(2):543-551. PubMed ID: 36155511
[TBL] [Abstract][Full Text] [Related]
37. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
38. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.
Risacher SL; Kim S; Nho K; Foroud T; Shen L; Petersen RC; Jack CR; Beckett LA; Aisen PS; Koeppe RA; Jagust WJ; Shaw LM; Trojanowski JQ; Weiner MW; Saykin AJ;
Alzheimers Dement; 2015 Dec; 11(12):1417-1429. PubMed ID: 25960448
[TBL] [Abstract][Full Text] [Related]
39. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
40. Distinct amyloid and tau PET signatures are associated with diverging clinical and imaging trajectories in patients with amnestic syndrome of the hippocampal type.
Lagarde J; Olivieri P; Tonietto M; Gervais P; Comtat C; Caillé F; Bottlaender M; Sarazin M
Transl Psychiatry; 2021 Sep; 11(1):498. PubMed ID: 34588422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
